{"nctId":"NCT02792699","briefTitle":"Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab","startDateStruct":{"date":"2016-05-17","type":"ACTUAL"},"conditions":["Arthritis, Rheumatoid"],"count":311,"armGroups":[{"label":"ABP 798 / ABP 798","type":"EXPERIMENTAL","interventionNames":["Drug: ABP 798"]},{"label":"Rituximab (US) / ABP 798","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ABP 798","Drug: Rituximab (US)"]},{"label":"Rituximab (EU) / Rituximab (EU)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Rituximab (EU)"]}],"interventions":[{"name":"ABP 798","otherNames":[]},{"name":"Rituximab (US)","otherNames":["Rituxan®"]},{"name":"Rituximab (EU)","otherNames":["MabThera®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men or women ≥ 18 and ≤ 80 years old\n* Subjects must be diagnosed with rheumatoid arthritis for at least 6 months before baseline\n* Active RA defined as ≥ 6 swollen joints and ≥ 6 tender joints at screening and baseline and at least one of the following at screening:\n\n  * erythrocyte sedimentation rate (ESR) ≥ 28 mm/hr\n  * serum C-reactive protein (CRP) \\> 1.0 mg/dL\n* Subjects must be taking methotrexate (MTX) for ≥ 12 consecutive weeks and on a stable dose of MTX 7.5 to 25 mg/week for ≥ 8 weeks prior to receiving the investigational product (IP), and be willing to remain on a stable dose throughout the study\n* Subject has no known history of active tuberculosis\n\nExclusion Criteria:\n\n* Class IV RA, Felty's syndrome or history of prosthetic or native joint infection\n* Major chronic inflammatory disease or connective tissue disease other than RA, with the exception of secondary Sjögren's syndrome\n* Use of commercially available or investigational biologic therapies for RA as follows:\n\n  * anakinra, etanercept within 1 month prior to first dose of IP\n  * infliximab, abatacept, tocilizumab, golimumab, certolizumab within 3 months prior to first dose of IP\n  * other experimental or commercially available biologic therapies for RA within 3 months or 5 half-lives (whichever is longer) prior to first dose of IP\n* Previous receipt of rituximab or a biosimilar of rituximab\n\nOther Inclusion/Exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf) After the Second Infusion of the First Dose","description":"Area under the serum concentration-time curve from time 0 extrapolated to infinity (AUCinf) following the second infusion of the first dose (day 15). Concentrations of ABP-798 and rituximab were quantified using a validated electrochemiluminescent method. AUCinf was estimated using the linear trapezoidal rule.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"149398","spread":"36.2"},{"groupId":"OG001","value":"172463","spread":"32.9"},{"groupId":"OG002","value":"158529","spread":"34.9"}]}]}]},{"type":"PRIMARY","title":"Maximum Observed Drug Concentration (Cmax) After the Second Infusion of the First Dose","description":"Maximum observed concentration following the second infusion of the first dose (day 15). Concentrations of ABP-798 and rituximab were quantified using a validated electrochemiluminescent method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"361","spread":"23.5"},{"groupId":"OG001","value":"394","spread":"22.0"},{"groupId":"OG002","value":"372","spread":"24.7"}]}]}]},{"type":"SECONDARY","title":"Area Under the Serum Concentration-time Curve From Predose on Day 1 to 14 Days Postdose (AUC0-14day)","description":"Area under the serum concentration-time curve from time 0 on day 1 prior to the first infusion of the first dose to 14 days postdose. Concentrations of ABP-798 and rituximab were quantified using a validated electrochemiluminescent method. AUC0-14day was estimated using the linear trapezoidal rule.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41445","spread":"28.8"},{"groupId":"OG001","value":"45161","spread":"24.7"},{"groupId":"OG002","value":"43291","spread":"29.6"}]}]}]},{"type":"SECONDARY","title":"Area Under the Serum Concentration-time Curve From Predose on Day 1 to Week 12 (AUC0-12wk)","description":"Area under the serum concentration-time curve from time 0 on day 1 prior to the first infusion of the first dose to week 12. Concentrations of ABP-798 and rituximab were quantified using a validated electrochemiluminescent method. AUC0-12wk was estimated using the linear trapezoidal rule.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"146369","spread":"34.3"},{"groupId":"OG001","value":"166995","spread":"30.5"},{"groupId":"OG002","value":"155240","spread":"33.7"}]}]}]},{"type":"SECONDARY","title":"Maximum Observed Drug Concentration (Cmax) After the First Infusion of the First Dose","description":"Concentrations of ABP-798 and rituximab were quantified using a validated electrochemiluminescent method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"298","spread":"26.1"},{"groupId":"OG001","value":"321","spread":"21.2"},{"groupId":"OG002","value":"304","spread":"25.5"}]}]}]},{"type":"SECONDARY","title":"Time of Maximum Observed Drug Concentration (Tmax) After the First and Second Infusions of the First Dose","description":"Concentrations of ABP-798 and rituximab were quantified using a validated electrochemiluminescent method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.50","spread":null},{"groupId":"OG001","value":"4.67","spread":null},{"groupId":"OG002","value":"4.68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.57","spread":null},{"groupId":"OG001","value":"3.67","spread":null},{"groupId":"OG002","value":"4.12","spread":null}]}]}]},{"type":"SECONDARY","title":"Last Measurable Serum Concentration After the Second Infusion up to Week 12 (Clast)","description":"Concentrations of ABP-798 and rituximab were quantified using a validated electrochemiluminescent method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.95","spread":"154"},{"groupId":"OG001","value":"8.52","spread":"145"},{"groupId":"OG002","value":"6.76","spread":"143"}]}]}]},{"type":"SECONDARY","title":"Terminal Elimination Half-life (t1/2)","description":"Concentrations of ABP-798 and rituximab were quantified using a validated electrochemiluminescent method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"335.62","spread":"38"},{"groupId":"OG001","value":"375.26","spread":"32"},{"groupId":"OG002","value":"334.57","spread":"40"}]}]}]},{"type":"SECONDARY","title":"Terminal Elimination Rate Constant (λz)","description":"Concentrations of ABP-798 and rituximab were quantified using a validated electrochemiluminescent method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00205","spread":"38.61018"},{"groupId":"OG001","value":"0.00187","spread":"33.44044"},{"groupId":"OG002","value":"0.00205","spread":"40.15779"}]}]}]},{"type":"SECONDARY","title":"Clearance (CL)","description":"Concentrations of ABP-798 and rituximab were quantified using a validated electrochemiluminescent method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01339","spread":"36.22558"},{"groupId":"OG001","value":"0.01160","spread":"32.94524"},{"groupId":"OG002","value":"0.01262","spread":"34.93316"}]}]}]},{"type":"SECONDARY","title":"Mean Residence Time (MRT)","description":"Concentrations of ABP-798 and rituximab were quantified using a validated electrochemiluminescent method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"549","spread":"26.7"},{"groupId":"OG001","value":"592","spread":"26.5"},{"groupId":"OG002","value":"557","spread":"26.8"}]}]}]},{"type":"SECONDARY","title":"Percent of AUC Extrapolation (AUC%Extrap)","description":"Percent of AUC extrapolated to infinity in AUCinf. Concentrations of ABP-798 and rituximab were quantified using a validated electrochemiluminescent method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.91","spread":"161"},{"groupId":"OG001","value":"2.62","spread":"146"},{"groupId":"OG002","value":"2.06","spread":"148"}]}]}]},{"type":"SECONDARY","title":"AUC0-12 wk/AUCinf","description":"Concentrations of ABP-798 and rituximab were quantified using a validated electrochemiluminescent method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":"3"},{"groupId":"OG001","value":"0.96","spread":"4"},{"groupId":"OG002","value":"0.97","spread":"3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Disease Activity Score 28-CRP at Week 24","description":"The DAS28 measures the severity of disease at a specific time and is derived from the following variables:\n\n* 28 tender joint count\n* 28 swollen joint count\n* C-reactive protein (CRP)\n* Patient's global health assessment measured on a 100 mm VAS, where 0 mm = no RA activity and 100 mm = worst RA activity imaginable.\n\nDAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.006","spread":"0.1313"},{"groupId":"OG001","value":"-2.116","spread":"0.1339"},{"groupId":"OG002","value":"-1.936","spread":"0.1349"},{"groupId":"OG003","value":"-2.026","spread":"0.1039"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Disease Activity Score 28-CRP at Weeks 8, 12, 40, and 48","description":"The DAS28 measures the severity of disease at a specific time and is derived from the following variables:\n\n* 28 tender joint count\n* 28 swollen joint count\n* C-reactive protein (CRP)\n* Patient's global health assessment measured on a 100 mm VAS, where 0 mm = no RA activity and 100 mm = worst RA activity imaginable.\n\nDAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.674","spread":"0.1259"},{"groupId":"OG001","value":"-1.738","spread":"0.1335"},{"groupId":"OG002","value":"-1.527","spread":"0.1330"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.746","spread":"0.1302"},{"groupId":"OG001","value":"-2.248","spread":"0.1357"},{"groupId":"OG002","value":"-2.016","spread":"0.1367"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.038","spread":"0.1440"},{"groupId":"OG001","value":"-2.293","spread":"0.1494"},{"groupId":"OG002","value":"-2.198","spread":"0.1489"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.243","spread":"0.1473"},{"groupId":"OG001","value":"-2.505","spread":"0.1553"},{"groupId":"OG002","value":"-2.323","spread":"0.1486"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an ACR20 Response","description":"A positive ACR20 response is defined if the following 3 criteria for improvement from baseline were met:\n\n* ≥ 20% improvement in 68 tender joint count;\n* ≥ 20% improvement in 66 swollen joint count; and\n* ≥ 20% improvement in at least 3 of the 5 following parameters:\n\n  * Patient's assessment of disease-related pain (measured on a 100 mm visual analog scale \\[VAS\\]);\n  * Patient's global health assessment (measured on a 100 mm VAS);\n  * Investigator's global health assessment (measured on a 100 mm VAS);\n  * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \\[HAQ-DI\\]);\n  * C-reactive protein concentration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.4","spread":null},{"groupId":"OG001","value":"60.0","spread":null},{"groupId":"OG002","value":"54.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.6","spread":null},{"groupId":"OG001","value":"73.3","spread":null},{"groupId":"OG002","value":"63.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.7","spread":null},{"groupId":"OG001","value":"66.7","spread":null},{"groupId":"OG002","value":"64.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.8","spread":null},{"groupId":"OG001","value":"73.7","spread":null},{"groupId":"OG002","value":"68.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.2","spread":null},{"groupId":"OG001","value":"79.8","spread":null},{"groupId":"OG002","value":"75.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an ACR50 Response","description":"A positive ACR50 response is defined if the following 3 criteria for improvement from baseline were met:\n\n* ≥ 50% improvement in 68 tender joint count;\n* ≥ 50% improvement in 66 swollen joint count; and\n* ≥ 50% improvement in at least 3 of the 5 following parameters:\n\n  * Patient's assessment of disease-related pain (measured on a 100 mm visual analog scale \\[VAS\\]);\n  * Patient's global health assessment (measured on a 100 mm VAS);\n  * Investigator's global health assessment (measured on a 100 mm VAS);\n  * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \\[HAQ-DI\\]);\n  * C-reactive protein concentration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.7","spread":null},{"groupId":"OG001","value":"29.3","spread":null},{"groupId":"OG002","value":"24.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.3","spread":null},{"groupId":"OG001","value":"47.5","spread":null},{"groupId":"OG002","value":"32.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.8","spread":null},{"groupId":"OG001","value":"39.2","spread":null},{"groupId":"OG002","value":"38.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.9","spread":null},{"groupId":"OG001","value":"57.9","spread":null},{"groupId":"OG002","value":"45.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.2","spread":null},{"groupId":"OG001","value":"58.3","spread":null},{"groupId":"OG002","value":"48.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an ACR70 Response","description":"A positive ACR70 response is defined if the following 3 criteria for improvement from baseline were met:\n\n* ≥ 70% improvement in 68 tender joint count;\n* ≥ 70% improvement in 66 swollen joint count; and\n* ≥ 70% improvement in at least 3 of the 5 following parameters:\n\n  * Patient's assessment of disease-related pain (measured on a 100 mm visual analog scale \\[VAS\\]);\n  * Patient's global health assessment (measured on a 100 mm VAS);\n  * Investigator's global health assessment (measured on a 100 mm VAS);\n  * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \\[HAQ-DI\\]);\n  * C-reactive protein concentration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null},{"groupId":"OG001","value":"12.0","spread":null},{"groupId":"OG002","value":"9.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.9","spread":null},{"groupId":"OG001","value":"19.8","spread":null},{"groupId":"OG002","value":"16.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.2","spread":null},{"groupId":"OG001","value":"19.6","spread":null},{"groupId":"OG002","value":"16.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.7","spread":null},{"groupId":"OG001","value":"27.7","spread":null},{"groupId":"OG002","value":"22.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.7","spread":null},{"groupId":"OG001","value":"39.3","spread":null},{"groupId":"OG002","value":"24.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Hybrid ACR","description":"The hybrid ACR combines the ACR 20/50/70 response with the mean percent change in all 7 ACR core components, thus providing a percent improvement from baseline on a continuous scale. For each participant, the mean percent improvement from baseline across the 7 ACR core set measures (tender joint count, swollen joint count, Patient's Global Assessment of Disease Activity, Investigator's Global Assessment of Disease Activity, disability index of the HAQ, and CRP) was calculated (a positive change indicates improvement, and the maximum worst change is limited to -100%) and the ACR20, ACR50, and ACR70 response is determined. The hybrid ACR is determined from a reference table taking into account both ACR response and mean percent improvement in the core set measures. Scores can range from -100% (maximal worsening) to 100% (maximal improvement).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.631","spread":"2.7287"},{"groupId":"OG001","value":"34.630","spread":"2.8058"},{"groupId":"OG002","value":"32.086","spread":"2.8628"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.604","spread":"2.8910"},{"groupId":"OG001","value":"44.828","spread":"2.9412"},{"groupId":"OG002","value":"38.664","spread":"3.0360"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.269","spread":"3.1660"},{"groupId":"OG001","value":"40.589","spread":"3.1781"},{"groupId":"OG002","value":"38.539","spread":"3.2436"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.042","spread":"3.1508"},{"groupId":"OG001","value":"43.250","spread":"3.1916"},{"groupId":"OG002","value":"41.078","spread":"3.2459"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.917","spread":"3.3878"},{"groupId":"OG001","value":"48.546","spread":"3.4870"},{"groupId":"OG002","value":"45.013","spread":"3.3942"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Complete Depletion in CD19+ Cell Count on Day 3","description":"Complete depletion of cluster of differentiation (CD) 19 positive cells was defined as a CD19+ cell count \\< 20 cell/μL (0.02 x 10⁹ cell/L).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.8","spread":null},{"groupId":"OG001","value":"96.9","spread":null},{"groupId":"OG002","value":"92.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Complete Depletion in CD19+ Cell Count","description":"Duration of CD19+ B-cell complete depletion was defined as the time from the first incidence of complete depletion of CD19+ cell count (CD19+ cell count \\< 20 cells/μL) to when the CD19+ cell count first increased to ≥ 20 cells/μL. Participants whose CD19+ cell count did not increase to ≥ 20 cells/μL were censored at the last CD19+ assessment date.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events After the First Dose","description":"Adverse events (AEs) were graded by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.03, where Grade 1 = mild AE, Grade 2 = moderate AE, Grade 3 = severe AE, Grade 4 = life-threatening AE, and Grade 5 = death due to AE.\n\nA serious AE (SAE) was defined as an AE that met at least 1 of the following serious criteria:\n\n* fatal\n* life-threatening\n* required inpatient hospitalization or prolongation of existing hospitalization\n* resulted in persistent or significant disability/incapacity\n* congenital anomaly/birth defect\n* other medically important serious event. The adverse events of interest prespecified for this study included infusion reactions including hypersensitivity, cardiac disorders, serious infections, progressive multifocal leukoencephalopathy, hematological reactions, hepatitis B reactivation, opportunistic infections, hypogammaglobulinemia, severe mucocutaneous reactions, and gastrointestinal perforation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Developed Anti-drug Antibodies","description":"Samples were first tested in an electrochemiluminescence (ECL)-based bridging immunoassay to detect antibodies capable of binding to ABP 798/rituximab (Binding Antibody Assay). Samples confirmed to be positive for binding antibodies were subsequently tested in a cell-based assay to determine neutralizing activity against ABP 798/rituximab (Neutralizing Antibody Assay).\n\nDeveloping antibody incidence was defined as participants with a negative or no binding antibody result at baseline and a positive antibody result at any post-baseline time point.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinically Significant Laboratory Findings","description":"Clinically significant clinical laboratory findings were defined as laboratory results that were ≥ Grade 3, based on the CTCAE version 4.03.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"54","spread":null},{"groupId":"OG002","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":104},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Rheumatoid arthritis","Nausea","Bronchitis"]}}}